RT Journal Article
SR Electronic
T1 A population-based study of the prevalence of COVID-19 infection in Espírito Santo, Brazil: methodology and results of the first stage
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.13.20130559
DO 10.1101/2020.06.13.20130559
A1 Gomes, Cristiana Costa
A1 Cerutti, Crispim
A1 Zandonade, Eliana
A1 Noia Maciel, Ethel Leonor
A1 de Alencar, Filomena Euridice Carvalho
A1 Almada, Gilton Luiz
A1 Cardoso, Orlei Amaral
A1 Jabor, Pablo Medeiros
A1 Zanotti, Raphael Lubiana
A1 Reuter, Tania Queiroz
A1 de Andrade, Vera Lucia Gomes
A1 Bastos, Whisllay Maciel
A1 de Medeiros, Nésio Fernandes
YR 2020
UL http://medrxiv.org/content/early/2020/06/16/2020.06.13.20130559.abstract
AB BACKGROUND COVID-19 is affecting almost the entire world, causing more than four hundred thousand deaths and undermining the health care systems, as much as the economy, of the afflicted countries. The strategies for prevention depend on largely lacking information, as infection prevalence and virus pathogenicity. This study aimed to determine the prevalence, the pathogenicity, and the speed of infection spreading in a large population in Brazil.MATERIALS AND METHODS This is a serial cross-sectional study designed on a population basis and structured over houses as the sampling units. The sampling consisted of four visits at 15 days intervals in randomly selected census-designated sectors of the State major municipalities (reference municipalities) and two visits at 30 days intervals in smaller municipalities of the same regions of those of reference. At each visit, the investigators sampled houses and sampled one individual in each house for data collection. After the informed consent, the investigators performed a rapid antibody detection test (Celer Technology, Inc) and applied a questionnaire containing clinical and demographic questions.RESULTS From May 13th to 15th, the investigators performed 6,393 rapid tests in 4,612 individuals of the reference municipalities, 1,163 individuals of the smaller municipalities, and 166 contacts of the positive individuals. Ninety-seven dwellers were positive in the reference municipalities, giving a prevalence of 2.1% (CI 95%: 1.67-2.52%). In the smaller municipalities, the figure was 0.26% (CI 95%: 0.05%-0.75%) (three positives). There was an association of the positive result with female sex (p = 0.013) and houses with five dwellers or more (p = 0.003). Seventy-eight positive individuals reported symptoms in the previous 15 days (80.4%), being anosmia (45.4%), cough (40.2%), and myalgia (38.1%) the more frequent. About one-third of them reported fever (28.9%).CONCLUSIONS The results reveal a still small prevalence of infection in the study area, despite the significant number of sick people overloading the health system. The figures indicate an important underreporting in the area and a frequency that still can grow, making necessary public health actions for the containment of the transmission.Competing Interest StatementNesio Fernandes de Medeiros Junior is the head of the Espirito Santo Department of Health, which funded this study. The other authors declare that they have no conflicts of interest.Clinical Trialcross-sectional studyFunding StatementThis work was funded by the Espirito Santo Department of HealthAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study had the approval of the Committee on Ethics of Research on Human Beings of the University Hospital Cassiano Antonio de Moraes of the Federal University of Espirito Santo, under the insertion number CCAE 31417020.3.0000.5064 and the approval number 4.009.337.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data will be provided by the investigators at a reasonable request